CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 20 target
Drug / intervention
Sarcoma-specific CAR-T cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03356782
NCT03356782Phase 1RecruitingOn Track
CompareCT.gov

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Shenzhen Geno-Immune Medical Institute·interventional·Posted Nov 29, 2017·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating Sarcoma-specific CAR-T cells for Sarcoma and 2 related conditions. Currently recruiting, targeting 20 participants across 1 site.

Detailed Summary

The aim of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines CAR T cells and IgT cells to treat sarcoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Osteoid Sarcoma, Ewing Sarcoma
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20182019202020212022202320242025202620272028202920302031
First PostedNov 29, 2017
Enrollment StartJun 1, 2026
Primary CompletionDec 31, 2029
Study CompletionDec 31, 2030
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 8.6 years agoPrimary completion in 3.5 years

Arms & Interventions

Sarcoma-specific CAR-T cellsexperimental

Peripheral blood mononuclear cells (PBMCs) of patients who have CD133, GD2, Muc1, CD117 or other marker positive sarcoma will be obtained through apheresis, and T cells will be activated and modified to sarcoma-specific CAR-T cells.

Biological: Sarcoma-specific CAR-T cells

Interventions

Sarcoma-specific CAR-T cellsbiological

1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV